


PHARMACEUTICAL 2017

Epizyme Inc. Rank 137 of 313







PHARMACEUTICAL 2017

Epizyme Inc. Rank 137 of 313



The relative strengths and weaknesses of Epizyme Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epizyme Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 325% points. The greatest weakness of Epizyme Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -141%, being 275% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	248,672
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,621
Liabilities, Non-Current	0
Other Assets	645
Other Compr. Net Income	-106
Other Expenses	0
Other Liabilities	0
Other Net Income	9,621
Property and Equipment	3,124
Research and Development	91,461
Revenues	0
Selling, General and Administrative Expense	28,372

Output Variable	Value in 1000 USD
Assets	252,441
Liabilities	21,621
Expenses	119,833
Stockholders Equity	230,820
Net Income	-110,212
Comprehensive Net Income	-110,265
Economic Capital Ratio	-141%

